Clinical Impact of Nivolumab in Sinonasal Mucosal Melanoma: A 14-Year Single-Center Retrospective Study and Comprehensive Literature Review
: Nivolumab was associated with longer survival in this small cohort in patients with SNMM, including those who discontinued therapy due to irAEs. Our data supports recent meta-analyses demonstrating a benefit of ICIs in SNMM.
Authors
- Ryoukichi Ikeda (ORCID: https://orcid.org/0000-0003-0076-6092)
- Ken Saijo (ORCID: https://orcid.org/0000-0003-0179-3789)
- Masashi Kuroki (ORCID: https://orcid.org/0000-0002-3199-009X)
- Takenori Ogawa (ORCID: https://orcid.org/0000-0003-1556-7328)
- Ryota Iinuma
- Natsuko Obara
- Ryo Kawaura (ORCID: https://orcid.org/0000-0002-8993-1834)
- Kosuke Terazawa (ORCID: https://orcid.org/0000-0002-0033-652X)
- Ryo Utakata
- Hiromasa Ishihara
- Miki Umeda
- Tatsuhiko Yamada
- Hiroshi Okuda
- Hirofumi Shibata
- Kenichi Mori
Institutions
- Mie University (JP)
- Tohoku University (JP)
- Gifu University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2026-04-06
- DOI
- https://doi.org/10.3390/cancers18071174
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00